<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2262">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131711</url>
  </required_header>
  <id_info>
    <org_study_id>B0012</org_study_id>
    <nct_id>NCT05131711</nct_id>
  </id_info>
  <brief_title>Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)</brief_title>
  <acronym>CSREIG</acronym>
  <official_title>Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas (inSituVac2)(CSREIG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate combined stereotactic radiosurgery and enhanced immunotherapy for&#xD;
      recurrent glioblastomas. Immune adjuvants will be injected intratumorally and systemically to&#xD;
      induce antitumor-specific immunity after radiation induced immunological tumor cell death&#xD;
      (ICD). With radiation, tumor cells release tumor antigens that are captured by antigen&#xD;
      presenting dendritic cells. Immune adjuvants promote the presentation of tumor antigens and&#xD;
      the priming of antitumor T lymphocytes. The combined treatment induces and amplifies the&#xD;
      specific antitumor immunity in patients with recurrent glioblastomas, prolonging survivals of&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recurrent glioblatoma (rGBM) is an aggressive malignancy with a poor prognosis. There is no&#xD;
      standard therapy and survival is less than 9 months. Recently, personalized cancer&#xD;
      immunotherapy has shown great promise in treating different types of cancers. However,&#xD;
      effective immunotherapies for rGBMs have yet to be established. The last clinical trial&#xD;
      (inSituVac1) showed promised results and this study was based on it. We will investigate&#xD;
      whether combining stereotactic radiosurgery with intratumoral and systemic administration of&#xD;
      enhanced immune adjuvants will improve the treatment outcome of rGBMs. We will use several&#xD;
      immune adjuvants that activate innate and adaptive immunity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2021</start_date>
  <completion_date type="Anticipated">November 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 16, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-related Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events during and after the combined treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Disease progression free survival time after combined treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival time after the combined treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>rGBM Group with combined stereotactic radiosurgery and enhanced immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with rGBMs will receive combined stereotactic radiosurgery and enhanced immunal adjuvants (GM-CSF, Sapylin, MnCl2). The safety and efficacy will be analyzed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rGBM Group with</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After biopsy or tumor resection, this rGBM group was treated with FDA-approved strategies proposed by the MDT group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Combined stereotactic radiosurgery and enhanced immunotherapy</intervention_name>
    <description>Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.</description>
    <arm_group_label>rGBM Group with combined stereotactic radiosurgery and enhanced immunotherapy</arm_group_label>
    <other_name>stereotactic radiosurgery and GM-CSF, Sapylin, MnCl2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Histopathologically confirmed rGBM&#xD;
&#xD;
          -  2. Age18-65&#xD;
&#xD;
          -  3. Participants had undergone maximal surgical resection&#xD;
&#xD;
          -  4. Amount of dexamethasone was not more than 2mg/ days&#xD;
&#xD;
          -  5. Ability and willingness to sign informed consent&#xD;
&#xD;
          -  6. Karnofsky Performance Score of 70 or more&#xD;
&#xD;
          -  7. Normal liver and kidney function&#xD;
&#xD;
          -  8. Not accepted other treatment plan during the immunotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Not conforming to the standard&#xD;
&#xD;
          -  2. Systemic illness or medical condition may pose additional risk,including cardiac,&#xD;
             incompensated renal or liver function abnormalities;inflammatory and immune system&#xD;
             diseases of rheumatic arthritis&#xD;
&#xD;
          -  3. Received other drugs for glioma therapy 60 days before participated&#xD;
&#xD;
          -  4. Allergy to immune adjuvant&#xD;
&#xD;
          -  5. Nervous system disease and diffuse leptomeningeal disease&#xD;
&#xD;
          -  6. Amount of dexamethasone was more than 2mg/days during the immunotherapy&#xD;
&#xD;
          -  7. Pregnant or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Song Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peijuan Ren, M.D.</last_name>
    <phone>+861059978039</phone>
    <email>ttyyirb@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Song Lin, M.D.</last_name>
      <phone>861059976509</phone>
      <email>linsong2005@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaohui Ren, M.D.</last_name>
      <phone>+861059976509</phone>
      <email>xiaohuiren@aliyun.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Song Lin</investigator_full_name>
    <investigator_title>Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>recurrent glioblastomas</keyword>
  <keyword>stereotactic radiosurgery</keyword>
  <keyword>enhanced immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

